Monday, June 15, 2026

Metabia Begins Dosing First Patient in Phase 1 Part 3 Trial of Obesity Drug DA-1726

Metabia begins Phase 1 trial for DA-1726, a dual-action obesity treatment, aiming for safety and efficacy in weight loss by 2026.

Yonsei University Develops AI Platform for Early Autism Screening and Treatment

Yonsei University is developing an AI platform for autism screening, aiming for early detection and practical use in clinical settings.

AI Surge Pushes TSMC to New Heights

Artificial intelligence (AI) stocks led not only...

Tag: shares

No posts to display

Top News

- Our Sponsors Ad -

Follow us